Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIROX2: S-1, Irinotecan, and Oxaliplatin in Gastric Cancer
NCT00512681Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2007
- Primary completion
- Jul 2009
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in gastric adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2007; status: completed.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00512681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00512681.